DRUG · Mapped RxNorm record
Abiraterone Acetate
Normalized identity: abiraterone acetateView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
NCT01637402
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Prednisone
Normalized identity: prednisoneView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Castration Resistant Prostate Cancerunresolved
Interventions
Abiraterone AcetateDRUG · verified · RxNorm: abiraterone acetate
PrednisoneDRUG · verified · RxNorm: prednisone
Sponsors & collaborators
Terence Friedlander, MDlead sponsor
Janssen Biotech, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01637402 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.